Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Mclean Hospital
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02304432CT.gov Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine | — | Completed | — | — | — |
NCT01981759CT.gov D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions | — | Completed | — | — | — |
NCT02769936CT.gov Glutamate, Learning, and Working Memory | — | Completed | — | — | — |
NCT00963924CT.gov D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia | — | Completed | — | — | — |
NCT00964041CT.gov Once Weekly D-cycloserine for Schizophrenia | — | Withdrawn | — | — | — |
NCT00742079CT.gov Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia | — | Completed | — | — | — |
NCT00455702CT.gov Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia | — | Completed | — | — | — |
NCT00222235CT.gov Adjunctive Treatment for Decreasing Symptoms of Schizophrenia | — | Completed | — | — | — |
NCT00000372CT.gov Glycine and D-Cycloserine in Schizophrenia | — | Withdrawn | — | — | — |
NCT00000371CT.gov Trial of D-Cycloserine in Schizophrenia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Schizophrenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dcs (this asset) | Mclean Hospital | Approved | BB · 68 |
| Xanomeline | European Group for Research In Schizophrenia | P4 | BBB |
| Trospium | European Group for Research In Schizophrenia | P4 | BBB |
| Lurasidone | Aziende Chimiche Riunite Angelini Francesco S.p.A | P4 | BBB |
| Asenapine | Noven Pharmaceuticals, Inc. | P4 | BBB |
| Brexpiprazole | Humanis Saglık Anonim Sirketi | P4 | BBB |
| Bitopertin | Hoffmann-La Roche | P3 | BBB |
| Roluperidone | Minerva Neurosciences | P3 | BBB |
| Raloxifene | Shanghai Mental Health Center | P4 | BBB |
+42 more in the Schizophrenia cohort
Other indications for Dcs
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar Disorder | — | P4 | BB · 69 |
| Delusional Disorder | — | P4 | BB · 67 |
| Schizoaffective Disorder | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dcs in Schizophrenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dcs-schizophrenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →